Natera, Alliance Foundation Trials Launch Phase 3 Trial for Breast Cancer Treatment Strategy

MT newswire2026/10/05 13:10

09:10 AM EDT, 10/05/2026 (MT Newswires) -- Natera (NTRA) and research organization Alliance Foundation Trials have launched a phase 3 trial evaluating a novel molecular residual disease-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer, the parties said Monday. The treatment strategy will pair investigational oral selective estrogen receptor degrader giredestrant, developed by Roche Group member Genentech, with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from treatment escalation with a CDK4/6 inhibitor, according to a statement. Alliance Foundation Trials expects to enroll over 2,000 patients with stage II-III ER-positive/HER2-negative breast cancer who are eligible for endocrine therapy at around 200 sites across the US and globally, the statement said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Viral Altcoin Defies Market Slumber With 53% Surge, BTC Calms at $83K: Weekend Watch

Cryptopotato•2026/10/11 10:21

Global Bank Stocks Sink as Bond Losses Top $326 Billion: Is Another SVB Coming?

BeInCrypto•2026/10/11 10:06

Exclusive Report - Sources Say INWIT Investors Are Raising Funds for a Possible Privatization Deal

路透社•2026/10/11 08:51

About 700,000 BTC have flowed out of exchanges in the past year.

AiCoin•2026/10/11 07:37